This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates

Newswire.ca - Tue Nov 7, 2023

Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024

Data from Cohort 2 of the FPI-1434 Phase 1 study anticipated around
year-end 2023

Read more at newswire.ca